Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III pediatric study of sublingual 5-grass pollen allergen tablets for grass pollen rhinoconjunctivitis
2005-002502-34Phase 3Terminated
- Sponsor
- Stallergenes Greer
- Start
- Oct 2005
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic rhinoconjunctivitis (ARC) comparing 5-grass pollen allergen extract tablets with Placebo (2 arms). Primary endpoint: Average Retrospective Rhinoconjunctivitis Total Symptom Score during the pollen period. Started Oct 2005; status: terminated.
02
Drugs
Oralair
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2005-002502-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002502-34.